Eupraxia Pharmaceuticals Inc. (EPRX) is a Biotechnology company in the Healthcare sector, currently trading at $7.22. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is EPRX = $19 (+163.2% upside).
Valuation: EPRX trades at a trailing Price-to-Earnings (P/E) of -8.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.82.
Net income is $39M (loss), growing at -21.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $153,953 against $82M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 15.12 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $86M.
Analyst outlook: 2 / 2 analysts rate EPRX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
